LEONARD P. STARK, District Judge.
On January 14, 2014, Plaintiff Kraft Foods Group Brands ("Kraft" or "Plaintiff) filed suit against Defendants TC Heartland and Heartland Packaging Corporation ("Heartland" or "Defendants") alleging infringement of U.S. Patent Nos. 8,293,299 (the "'299 patent"), 8,603,557 (the "'557 patent"), and 8,511,472 (the "'472 patent"). These patents generally relate to shelf-stable, flavored liquid beverage concentrates and packaging for them.
The parties submitted technology tutorials (D.I. 126, 128) and claim construction briefs (D.I. 108, 109, 129, 131). The Court held a hearing on January 5, 2016 to address the pending claim construction disputes. (See D.I. 192 ("Tr."))
On January 13, without seeking leave and without additional submissions being requested by the Court, Heartland filed a "Letter Regarding Questions Asked of Heartland at Markman Hearing." (D.I. 160) Understandably, Kraft felt it necessary to respond with its own posthearing letter, and did so on January 19. (D.I. 162) In its letter, Kraft advised the Court that Heartland had not asked Kraft "whether it would oppose Heartland's filing of the letter." (D.I. 162) Although the far preferable practice in such circumstances is to confer with opposing counsel and present a joint request for leave to file an uninvited post-hearing submission,
The ultimate question of the proper construction of a patent is a question of law. See Teva Pharm. USA, Inc. v. Sandoz, Inc., 135 S.Ct. 831, 837 (2015) (citing Markman v. Westview Instruments, Inc., 517 U.S. 370, 388-91 (1996)). "It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude." Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (internal quotation marks omitted). "[T]here is no magic formula or catechism for conducting claim construction." Id. at 1324. Instead, the court is free to attach the appropriate weight to appropriate sources "in light of the statutes and policies that inform patent law." Id.
"[T]he words of a claim are generally given their ordinary and customary meaning . . . [which is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application." Id. at 1312-13 (internal citations and quotation marks omitted). "[T]he ordinary meaning of a claim term is its meaning to the ordinary artisan after reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent specification "is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term." Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996).
While "the claims themselves provide substantial guidance as to the meaning of particular claim terms," the context of the surrounding words of the claim also must be considered. Phillips, 415 F.3d at 1314. Furthermore, "[o]ther claims of the patent in question, both asserted and unasserted, can also be valuable sources of enlightenment . . . [b]ecause claim terms are normally used consistently throughout the patent. . . ." Id. (internal citation omitted).
It is likewise true that "[differences among claims can also be a useful guide. . . . For example, the presence of a dependent claim that adds a particular limitation gives rise to a presumption that the limitation in question is not present in the independent claim." Id. at 1314-15 (internal citation omitted). This "presumption is especially strong when the limitation in dispute is the only meaningful difference between an independent and dependent claim, and one party is urging that the limitation in the dependent claim should be read into the independent claim." SunRace Roots Enter. Co., Ltd. v. SRAM Corp., 336 F.3d 1298, 1303 (Fed. Cir. 2003).
It is also possible that "the specification may reveal a special definition given to a claim term by the patentee that differs from the meaning it would otherwise possess. In such cases, the inventor's lexicography governs." Phillips, 415 F.3d at 1316. It bears emphasis that "[e]ven when the specification describes only a single embodiment, the claims of the patent will not be read restrictively unless the patentee has demonstrated a clear intention to limit the claim scope using words or expressions of manifest exclusion or restriction." Hill-Rom Sen's., Inc. v. Stryker Corp., 755 F.3d 1367, 1372 (Fed. Cir. 2014) (quoting Liebel-Flarsheim Co. v. Medrad, Inc., 358 F.3d 898, 906 (Fed. Cir. 2004)) (internal quotation marks omitted).
In addition to the specification, a court "should also consider the patent's prosecution history, if it is in evidence." Markman v. Westview Instruments, Inc., 52 F.3d 967, 980 (Fed. Cir. 1995), aff'd, 517 U.S. 370 (1996). The prosecution history, which is "intrinsic evidence," "consists of the complete record of the proceedings before the PTO [Patent and Trademark Office] and includes the prior art cited during the examination of the patent." Phillips, 415 F.3d at 1317. "[T]he prosecution history can often inform the meaning of the claim language by demonstrating how the inventor understood the invention and whether the inventor limited the invention in the course of prosecution, making the claim scope narrower than it would otherwise be." Id.
In some cases, "the district court will need to look beyond the patent's intrinsic evidence and to consult extrinsic evidence in order to understand, for example, the background science or the meaning of a term in the relevant art during the relevant time period." Teva, 135 S. Ct. at 841. Extrinsic evidence "consists of all evidence external to the patent and prosecution history, including expert and inventor testimony, dictionaries, and learned treatises." Markman, 52 F.3d at 980. For instance, technical dictionaries can assist the court in determining the meaning of a term to those of skill in the relevant art because such dictionaries "endeavor to collect the accepted meanings of terms used in various fields of science and technology." Phillips, 415 F.3d at 1318. In addition, expert testimony can be useful "to ensure that the court's understanding of the technical aspects of the patent is consistent with that of a person of skill in the art, or to establish that a particular term in the patent or the prior art has a particular meaning in the pertinent field." Id. Nonetheless, courts must not lose sight of the fact that "expert reports and testimony [are] generated at the time of and for the purpose of litigation and thus can suffer from bias that is not present in intrinsic evidence." Id. Overall, while extrinsic evidence "may be useful" to the court, it is "less reliable" than intrinsic evidence, and its consideration "is unlikely to result in a reliable interpretation of patent claim scope unless considered in the context of the intrinsic evidence." Id. at 1318-19. Where the intrinsic record unambiguously describes the scope of the patented invention, reliance on any extrinsic evidence is improper. See Pitney Bowes, Inc. v. Hewlett-Packard Co., 182 F.3d 1298, 1308 (Fed. Cir. 1999) (citing Vitronics, 90 F.3dat 1583).
Finally, "[t]he construction that stays true to the claim language and most naturally aligns with the patent's description of the invention will be, in the end, the correct construction." Renishaw PLC v. Marposs Societa'per Azioni, 158 F.3d 1243, 1250 (Fed. Cir. 1998). It follows that "a claim interpretation that would exclude the inventor's device is rarely the correct interpretation." Osram GmbH v. Int'l Trade Comm'n, 505 F.3d 1351, 1358 (Fed. Cir. 2007) (quoting Modine Mfg. Co. v. U.S. Int'l Trade Comm'n, 75 F.3d 1545, 1550 (Fed. Cir. 1996)).
This term relates to the patented flavored beverage concentrate. The patent recites a general recipe for the concentrate. The amount of each ingredient is listed as the percentage of the weight of the concentrate attributable to that ingredient. A range of possible weight percentages is listed for each ingredient, such than many different compositions are possible. For example, claim 1 of the '299 patent recites a concentrate comprising "up to" 10% buffer by weight, 15-30% acid by weight, 1-30% flavoring by weight, and 30-65% water by weight.
To understand the parties' dispute, it is helpful to display claim 1's "recipe" in the form of a table:
A 100 gram sample of a buffered concentrate prepared according to this recipe might contain the following weights of each ingredient:
The disputed term adds the limitation that the amount of buffer in the claimed buffered concentrate must "provide the concentrate with at least about 5 times more acid than an otherwise identical non-buffered concentrate having the same pH." In order to know whether a particular buffered concentrate (such as the exemplary concentrate set forth above) satisfies this claim limitation, it is necessary to compare that buffered concentrate to the appropriate "otherwise identical non-buffered concentrate having the same pH.'"
The parties' dispute centers on what it means for a buffered concentrate to be "otherwise identical'' to a concentrate containing no buffer and having the same pH. The disagreement arises because the non-buffered version of the concentrate contains far less acid than the buffered version. This raises the question of what it means for a claimed concentrate to be "otherwise identical" to another concentrate that completely lacks one of its four components (buffer) and contains substantially less of another component (acid).
There is some agreement between the parties as to what is contained in the comparison "otherwise identical" non-buffered concentrate. First, the parties agree that the non-buffered concentrate does not contain any buffer; that is what makes it "non-buffered." Second, the parties agree that the non-buffered concentrate has far less acid than the buffered concentrate. Specifically, since the buffered concentrate must have "at least 5 times more acid" than the nonbuffered concentrate, it follows that the non-buffered concentrate must have no more than onefifth as much acid as the buffered concentrate. However, the parties disagree as to what, if anything, "replaces" the buffer and acid that are in the buffered concentrate but are not in the non-buffered concentrate.
Kraft argues that, for a person of ordinary skill in the art ("POSA"), the answer would be clear: an "identical" concentrate is one that contains an identical
By contrast, Heartland contends that a POSA reviewing the patent and the prosecution history would not know with reasonable certainty what, if anything, "replaces" the "missing" buffer and acid in the comparison non-buffered concentrate.
Most important, in Heartland's view, is that all three of these possibilities (and possibly others) could occur to a POSA reading the patent and prosecution history. Thus, the patent fails to "inform those skilled in the art about the scope of the invention with reasonable certainty," Nautilus, 134 S. Ct. at 2129, and the claims must be held invalid due to indefiniteness.
At bottom, then, Kraft contends that there is one and only one way that a POSA would understand the term "otherwise identical" in this context. Kraft is so certain of this position that it urges the Court not even to construe the disputed claim term, but instead to adopt an unspecified "ordinary and customary meaning as understood by one of ordinary skill in the art." In light of the parties' dispute, this non-particularized formulation would be entirely unhelpful to the jury.
Heartland, on the other hand, contends that Kraft's proposed construction only captures one of several ways a POSA might understand an "otherwise identical non-buffered concentrate having the same pH." Among the other alternatives is the one depicted above in Table 4. That alternative, reduced to words, might be: an "otherwise identical non-buffered concentrate having the same pH" means "one that includes no buffer and no more than one-fifth the weight of acid of a buffered concentrate having identical weights of each ingredient other than acid, buffer, and water."
The record before the Court does not conclusively support either construction. Some intrinsic evidence supports Kraft's proposed "weight percentage" construction, including the fact that the claims describe the "recipe" for the concentrate in terms of weight percentage.
After careful consideration of this record, the Court finds that it is presently unable to resolve the parties' dispute with respect to this claim term. It is not clear at this time whether Kraft's "weight percentage" construction, Heartland's "flavoring ratio" construction, or some other alternative is correct. Moreover, Heartland has failed to meet the heavy burden it has taken on in seeking to invalidate the claims. To demonstrate indefiniteness, a party must demonstrate that a POSA at the time of the invention would not have known, with reasonable certainty, the scope of the claims. See Nautilus, 134 S. Ct. at 2129. Though the Court is not able to ascertain the meaning of this term based on the record before it, the Court is also not convinced that a person of ordinary skill in the art would have been unable to do so.
Under these circumstances, the Court requires additional input from the parties to assist it in evaluating how a POSA would have understood the this term in the context of the patent. It may be helpful for the Court to hear directly from experts as to how a POSA would modify a buffered concentrate that is within the scope of the claims (e.g., the one described in Table 2 above) to arrive at the "otherwise identical" non-buffered concentrate. See generally Teva Pharm. USA, Inc., 135 S. Ct. at 841 ("In some cases . . . the district court will need to look beyond the patent's intrinsic evidence and to consult extrinsic evidence in order to understand, for example, the background science or the meaning of a term in the relevant art during the relevant time period."). It might also be useful to examine laboratory notebooks and similar materials created by the inventors or those working with them to see how they, in fact, moved between buffered concentrates and "otherwise identical" non-buffered concentrates.
Upon review of such materials, the Court may ultimately agree with Kraft that a POSA would always and necessarily understand the "otherwise identical" non-buffered concentrate to look like what is depicted above in Table 3. Alternatively, the Court may eventually be persuaded that one of Heartland's proposals for how a POSA would understand the "otherwise identical" non-buffered concentrate (such as the one exemplified in Table 4 above) is correct. Yet another possibility is that the Court will in the end agree with Heartland that the claims fail to inform a POSA with reasonable certainty of how to understand the "otherwise identical" nonbuffered concentrate and, therefore, that the claims are indefinite and invalid. By separate Order, the Court will direct the parties to provide the Court with their proposal(s) for additional proceedings that will allow the Court to resolve this claim construction dispute.
The parties agree that the plain and ordinary meaning of "selected" is "chosen" or "picked." (D.I. 108 at 10; D.I. 131 at 12) Heartland argues, nonetheless, that an alternative construction is required because the patentee disclaimed this plain and ordinary meaning during prosecution.
Heartland's position rests on the significance of a claim amendment made during the prosecution of the '299 patent. After the Examiner rejected a claim which had required that "the ratio of acid and buffer'" in the claimed concentrate be
In Heartland's view, this record shows that Kraft "discarded" the term "effective" during prosecution, thus precluding Kraft from arguing here that "selected" essentially means "effective." (D.I. 108 at 10) The Court disagrees.
A claim amendment amounts to a disclaimer if the patentee narrowed the claim in order to make it patentable. See Research Plastics, Inc. v. Fed. Packaging Corp., 421 F.3d 1290, 1297 (Fed. Cir. 2005). But not every amendment gives rise to a disclaimer; an amendment limits claim scope only if a patentee "took a position before the PTO that would lead a competitor to believe that the applicant had disavowed coverage of the relevant subject matter." Schwing GmbH v. Putzmeister Aktiengesellschaft, 305 F.3d 1318, 1324 (Fed. Cir. 2002). Here, the prosecution history shows that the patentee clarified, rather than narrowed, the scope of the claims. That is, the patentee changed the word "effective'' to "selected" in order to harmonize the language of the claims with the patentee's stated position that a person of ordinary skill in the art would know how much acid and buffer to use to meet the claim limitations.
Because the patentee amended the claims to clarify, rather than narrow, their scope, the patentee's amendment did not disclaim the plain and ordinary meaning of the claims.
While the parties agree that "about" means "approximately," they disagree as to whether this construction imparts numerical limitations on the pH values listed in the claim. Heartland contends that specific limitations are necessary to ensure that Kraft cannot recapture claim scope disclaimed during prosecution. Kraft counters that the patentee did not disclaim patent scope during prosecution and further that Heartland's proposed construction is improperly specific. The Court agrees with Heartland that the patentee disclaimed claim scope during prosecution, but also with Kraft that Heartland's proposed construction imparts improperly rigid numerical limitations on the claims.
Heartland's prosecution history disclaimer argument is based on a narrowing amendment. In its initial application, the patentee claimed concentrates having a pH in the range of "about 1.4 to about 3.0." (D.I. 109-2 at 116-19) The Examiner rejected the claims as obvious, citing a prior art beverage concentrate having a pH of 2.5 and appearing to meet each of the other claim limitations. (Id. at 128-29) In response, the patentee narrowed the claimed pH range to "about 1.9 to about 2.4." (Id. at 137)
"Under the doctrine of prosecution disclaimer, a patentee may limit the meaning of a claim term by making a clear and unmistakable disavowal of claim scope during prosecution." Purdue Pharma L.P. v. Endo Pharm., Inc., 438 F.3d 1123, 1136 (Fed. Cir. 2006). A disavowal is unmistakable when a patentee "characterizes an aspect of his invention in a specific manner to overcome prior art." Id. In determining whether this occurred, it is proper to consider the entire intrinsic record, including the patentee's comments during prosecution. See Rheox, Inc. v. Entact, Inc., 276 F.3d 1319, 1325 (Fed. Cir. 2002)
Here, it is clear from the intrinsic record that the patentee narrowed the claims to overcome the prior art cited by the Examiner in rejecting the pre-amendment claims as obvious. After receiving the Examiner's initial rejection, the patentee met with the Examiner to discuss the application. The Examiner explained that the patentee could likely overcome the prior art by narrowing the claimed pH range. (D.I. 109-2 at 145) The Examiner also told the patentee that it would be advisable to bolster the case for non-obviousness by submitting declarations discussing "the challenges in developing the claimed concentrates and skepticism of others during development." (Id.) Citing the Examiner's advice, the patentee responded to the initial rejection by narrowing the claimed pH range and submitting two expert declarations. (Id.) Each of the expert declarations opines why the patentee's narrowed pH range was not obvious at the time of the invention. (Id. at 148-57) Taken together, this evidence demonstrates that the amendments were designed to overcome the Examiner's obviousness rejection. Thus, the patentee's amendment disclaimed concentrates with a pH of 2.5 or more. See Southwall Techs., Inc. v. Cardinal IG Co., 54 F.3d 1570, 1576 (Fed. Cir. 1995) ("The prosecution history limits the interpretation of claim terms so as to exclude any interpretation that was disclaimed during prosecution.").
Having found that the patentee disclaimed some claim scope, the Court next turns to the construction of the term "about." In general, "the word `about' does not have a universal meaning in patent claims," but instead "depends upon the technological facts of the particular case." Ortho-McNeil Pharm., Inc. v. Caraco Pharm. Labs., Ltd., 476 F.3d 1321, 1326 (Fed. Cir. 2007) (internal quotation marks omitted). "Although it is rarely feasible to attach a precise limit to `about,' the usage can usually be understood in light of the technology embodied in the invention." Modine Mfg. Co. v. U.S. Int'l Trade Comm'n, 75 F.3d 1545, 1554 (Fed. Cir. 1996), reinstated by 535 U.S. 722 (and abrogated by Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 234 F.3d 558 (Fed. Cir. 2000)). To determine any numerical limitations resulting from an "about" term, a court must "consider how the term was used in the patent specification, the prosecution history, and the other claims." Id. Where this intrinsic evidence does not provide a sufficient basis for determining the appropriate construction, a court may also consider relevant extrinsic evidence of "technologic and stylistic context." Pall Corp. v. Micron Separations, 66 F.3d 1211, 1217 (Fed. Cir. 1995). After construing the claim with whatever "`specificity and precision is warranted by the language of the claim and the evidence bearing on the proper construction, the task of determining whether the construed claim reads on the accused product is for the finder of fact." PPG Indus, v. Guardian Indus, Corp., 156 F.3d 1351, 1355 (Fed. Cir. 1998).
None of this requires the Court to adopt Heartland's position that, in order to prevent Kraft from recapturing the disclaimed pH value of 2.5, the Court must construe "about" only to include pH values of up to precisely 2.45 — halfway between the upper end of the claimed range ("to about 2.4") and the disclaimed value of 2.5. Defendants have not pointed to intrinsic evidence, nor to "technological facts" or "technological and stylistic context," to support this specific numerical limit. See Pall Corp., 66 F.3d at 1217; UCB, Inc. v. KVPharm. Co., 2009 WL 2524519, at *5-6 (D. Del. 2009). The Court will not, then, as a matter of law, construe the claim limitation as being bound precisely at a pH of 2.45. See Merck & Co., Inc. v. Teva Pharms. USA, Inc., 395 F.3d 1364, 1369-70 (Fed. Cir. 2005) (holding that "about" should be given its ordinary and accepted meaning of "approximately" unless patentee clearly redefines "about" in specification); see also PPG Indus., 156 F.3d at 1355 ("Claims are often drafted using terminology that is not as precise or specific as it might be. . . . That does not mean, however, that a court, under the rubric of claim construction, may give a claim whatever additional precision or specificity is necessary to facilitate a comparison between the claim and the accused product."); W.L. Gore & Associates, Inc. v. Garlock, Inc., 842 F.2d 1275, 1280 (Fed. Cir. 1988) (abrogated on other grounds) ("Whether an imprecise claim limitation . . . is literally met, is a question of fact for the trial court.").
Rather, the Court will ensure that the disclaimed value of 2.5 does not provide a basis for a finding of literal infringement by construing the claim limitation as "a pH of approximately 1.9 to 2.4, and less than 2.5."
For the reasons set forth above, the Court will construe this term as "a pH of up to approximately 2.4, and less than 2.5."
Again the parties dispute whether the word "about" imparts strict numerical limitations in the context of these claims. Again the source of the debate is a narrowing amendment. In the same office action described above in connection with the pH terms, the patentee amended the water and acid contents of the claimed concentrates. The patentee amended the range of acid contents from "about 5.0 to about 30.0 percent acid" to "about 15.0 to about 30.0 percent acid." (D.I. 109-2 at 137) At the same time, the patentee amended the range of possible water contents from "about 30 to about 80 percent water" to "about 30 to about 65 percent water." (Id.)
Even assuming these changes to the acid and water ranges constitute disclaimers, as Heartland insists, this is still not a persuasive basis to adopt Heartland's precise numerical construction. Just as discussed above with respect to the disputed pH terms, it is proper to assign "about" its plain and ordinary meaning of "approximately" here because there is no evidence to support rigid numerical limitations.
The parties appear to have no genuine dispute about the meaning of this term. They agree that this limitation requires a non-zero quantity of buffer. (D.I. 129 at 17; D.I. 131 at 17) The Court's construction clarifies this agreement and also avoids imposing rigid numerical limitations to the term "about" (for the reasons already given above).
The parties disagree about whether the preamble ("[a] container containing a liquid concentrate and configured for squeezing to dispense a jet of the liquid concentrate") of the patent's sole independent claim is limiting. "In general, a preamble limits the invention if it [either] recites essential structure or steps, or if it is necessary to give life, meaning, and vitality to the claim." Catalina Mktg. Int'l v. Coolsavings.com, Inc., 289 F.3d 801, 808 (Fed. Cir. 2002) (internal quotation marks omitted). A preamble meets these requirements when the prosecution history reveals that its limitations were "patentably significant." Marvin v. Griffin, 599 F.3d 1290, 1294 (Fed. Cir. 2010) For example, "clear reliance on the preamble during prosecution to distinguish the claimed invention from the prior art transforms the preamble into a claim limitation because such reliance indicates the use of the preamble to define, in part, the claimed invention." Catalina Mktg., 289 F.3d at 808. Here, the prosecution history demonstrates that the patentee relied upon the features recited in the preamble in order to overcome an obviousness rejection. (D.I. 109-5 at 90-91) Thus, the Court finds that the preamble of the claim recites essential structure and construes the preamble of the claim as limiting.
Heartland contends that the packaging claims of the '472 and '557 patents should be construed as encompassing only "approximate copies" of the embodiments disclosed in the specification. In support of its argument, Heartland cites the Supreme Court decision in Eibel Process Co. v. Minn. & Ont. Paper Co., 261 U.S. 45, 63 (1923), and in particular the following except:
Heartland argues that the packaging inventions disclosed in the '472 and '557 patents were "at best minor improvements over prior tapered-top packaging art" and, therefore, Eibel commands that the claims of these patents "be given narrow scope and construed as encompassing only approximate copies of the container described in the specifications of the patents." (D.I. 108 at 19-21) (internal quotation marks omitted)
Kraft counters that the Eibel analysis Heartland advocates is out of step with the "modern" approach to claim construction. (Tr. at 110) As Kraft points out, Heartland in its briefing did not cite even once to the Federal Circuit's en banc decision in Phillips. (Tr. at 12; see also id. at 17)
There are many problems with Heartland's position. First among them is that Phillips is binding precedent on this Court, which the Court must follow in construing disputed claim terms. Of course the Court must also follow precedent of the U.S. Supreme Court, but Heartland has failed to show that there is any inconsistency between Phillips and any decision of the Supreme Court, including Eibel.
Second, even were this Court to choose to be the first to apply Eibel in the manner Heartland requests, it is entirely unclear how the Court would do so. Heartland does not point to specific claim language and propose a construction for the Court to evaluate. Instead, Heartland broadly requests "an instruction to the jury that the packaging limitations of the '472 and '557 patents should encompass only approximate copies of the embodiments disclosed." (Tr. 104-05) Even if the Court agreed with Heartland, what precisely would the Court tell the jury "approximate copies" means?
Nor does Heartland tell the Court how to assess whether the patents-in-suit constitute a substantial advancement of the art or merely a slight step forward. Must the Court undertake a thorough examination of the scope and content of the prior art? Should the Court consider extrinsic evidence in undertaking such an evaluation? If so, how would such regular reliance on extrinsic evidence be consistent with the Supreme Court's recent discussion of the use of extrinsic evidence in claim construction, see Teva, 135 S. Ct. at 841 ("In
Third, there appears to be a substantial difference between the form of the claims at issue in Eibel and those at issue here. Each of the claims in Eibel is directed to "[a] Fourdrinier machine [having certain characteristics],
For at least these reasons, the Court rejects Heartland's request to limit the claims of the '472 and '557 patents to just approximate copies of the expressly disclosed embodiments.
The Court construes the disputed terms as explained above. An appropriate Order follows.